A judge has granted law firm Sparke Helmore’s bid for additional security in a negligence lawsuit brought by a property developer, but agreed the $215,000 sought by the firm was excessive.
The former CEO of failed coconut water venture CoCo Joy, which once sponsored the Manly-Warringah Sea Eagles NRL team, faces charges he managed the company while disqualified due to bankruptcy.
The High Court has thrown out sacked climate skeptic professor Peter Ridd’s appeal of his dismissal by James Cook University, finding protection of intellectual freedom is not a “general freedom of speech”.
The competition regulator has filed court action seeking an injunction to stop Virtus Health from completing the purchase of rival Adora Fertility on Friday while a merger review is still in progress.
Google has urged a court to stay a competition lawsuit brought by Epic Games, saying new evidence showed the Fortnite game maker would not be disadvantaged if the case was heard in California, as the Full Court found it would in a similar challenge by Apple.
Mining magnate Clive Palmer and two of his mining firms have lost a High Court challenge seeking to overturn a Western Australian law which prevented him from suing the state government for $30 billion over mining tenements in the Pilbara.
Botox drug maker Allergan has secured an injunction against a Sydney-based cosmetics company which sought to “leverage” the reputation of the well-known injectable to sell its Freezeframe line of anti-aging topical creams.
The Commonwealth Bank’s wealth management unit has agreed to cough up $20 million in penalties for misleading thousands of fund members during the transition to MySuper accounts, but steadfastly maintains its conduct was not part of a “nefarious” plot for profits.
The Murray Darling Basin Authority can’t rely on defences claiming it is a “public or other authority” to limit the liability of a class action brought over alleged negligent water management, an appeals court has found.
Danish drug maker Lundbeck has told the High Court it did not contract away a royalty-free licence to generic drug maker Sandoz to sell blockbuster antidepressant Lexapro, saying such a decision would be commercial “madness”.